Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LZ7E
|
|||
| Former ID |
DIB009127
|
|||
| Drug Name |
TP-434
|
|||
| Synonyms |
TP-038; TP-120; TP-170; TP-221; TP-271; TP-787; Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals; Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals; Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals; Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals; TP-434 (oral, multidrug-resistant bacterial infections); TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Intra-abdominal infection [ICD-11: 1A40; ICD-10: A00-B99] | Approved | [1] | |
| Influenza virus infection [ICD-11: 1E30-1E32] | Phase 2 | [2] | ||
| Company |
Tetraphase Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H31FN4O8
|
|||
| Canonical SMILES |
CN(C)C1C2CC3CC4=C(C=C(C(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F
|
|||
| InChI |
1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
|
|||
| InChIKey |
AKLMFDDQCHURPW-ISIOAQNYSA-N
|
|||
| CAS Number |
CAS 1207283-85-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial 30S ribosomal RNA (Bact 30S rRNA) | Target Info | Inhibitor | [1] |
| Bacterial Ribosome (Bact RIBS) | Target Info | Modulator | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13. | |||
| REF 2 | ClinicalTrials.gov (NCT01265784) Study to Compare TP-434 and Ertapenem in CA Complicated Intra-abdominal Infections. U.S. National Institutes of Health. | |||
| REF 3 | Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012 May;56(5):2559-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.